EGFR and lung adenocarcinoma: However, evidence that the co-occurrence of the two driver mutations is not uncommon, and that such cases might benefit from dual treatments with both EGFR and ALK TKIs, has recently been reported.[41] When treated with a single TKI, ALK TKI might be a better choice than EGFR TKI.[41] It is highly likely that in the near future, comprehensive molecular diagnoses for lung adenocarcinoma will include both EGFR and ALK testing.